- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04846816
A Study to Assess Safety and Efficacy of a Novel Patch Infusor Device and Novel SUBCUTaneous Furosemide Formulation Combination in Patients With Heart Failure (SUBCUT-HF I)
November 16, 2021 updated by: SQ Innovation, Inc.
An Open Label, Single Dose Study to Assess Safety and Efficacy of a Novel Patch Infusor Device and Novel SUBCUTaneous Furosemide Formulation Combination in Patients With Heart Failure: a Phase I Clinical Trial
This is a single-centre, prospective, open-label, non-comparative clinical trial assessing the on-body performance of an investigational drug delivery device (SQIN-Infusor) in patients hospitalised due to HF.
Study Overview
Detailed Description
The investigational product consists of a novel higher concentration (30mg/mL) furosemide formulation developed for subcutaneous administration and a novel patch pump placed on the abdominal skin.
This trial will investigate the on body performance of novel patch pump delivering the novel formulation.
Study parameters include pharmacokinetic measurements and diuretic response following subcutaneous administration of 80mg of furosemide solution in 2.7mL in patients with heart failure (HF).
Recruitment will be restricted to 1 site with a recruitment target of 20 patients.
All trial related activities will be conducted in an inpatient environment.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Glasgow, United Kingdom, G51 4TF
- Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
• Written informed consent
- Male or female ≥18 years of age
- Meet ESC criteria for diagnosis of HF(4)
- Inpatient with a primary diagnosis of HF requiring treatment with intravenous furosemide at dose
Exclusion Criteria:
• Unable to consent to inclusion in study due to lack of capacity
- Requiring treatment with intravenous furosemide at dose >200 mg per day as determined by the usual care team
- Current inotropes, vasopressors or intra-aortic balloon pump therapy
- Concomitant use of diuretics in 12 hours preceding administration of study drug with SQIN-Infusor
- Systolic blood pressure (SBP) <90 mmHg
- Pregnancy or breastfeeding
- Left sided valve disease with planned surgery or percutaneous intervention
- Type 1 myocardial infarction during index hospitalisation (type 2 myocardial infarctions are allowed)(5)
- Any surgical or medical condition which prevents patient from ambulation during the infusion
- Renal impairment, defined as eGFR < 30 mL/min/1.73 m2 at screening.
- Patient on active cardiac transplant waiting list
- Potassium <3.0 mmol/L
- Potassium >6.0 mmol/L
- Sodium <125 mmol/L
- Any contraindications for furosemide administration as per furosemide SmPC
- Any surgical or medical conditions, which in the opinion of the investigator may pose an undue risk to the subject, interfere with participation in the study or which may affect the integrity of the data
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SQIN-01
The drug and device combination is called SQIN-01.
SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
|
The drug and device combination is called SQIN-01.
SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To investigate the safety, tolerability, efficacy and on-body performance of a novel patch infusor device and novel furosemide formulation combination (SQIN-01).
Time Frame: 24 hours from start of infusion
|
Safety as determined by treatment emergent adverse events and adverse drug events
|
24 hours from start of infusion
|
Infusion site pain
Time Frame: During 5 hour infusion
|
Measured on a scale of 0 = no pain to 10 = most pain
|
During 5 hour infusion
|
Any device failures
Time Frame: During 5 hour infusion
|
Any device failures
|
During 5 hour infusion
|
Serum furosemide concentration
Time Frame: At baseline
|
Serum furosemide concentration
|
At baseline
|
Serum furosemide concentration
Time Frame: At 60 minutes
|
Serum furosemide concentration
|
At 60 minutes
|
Serum furosemide concentration
Time Frame: At 240 minutes
|
Serum furosemide concentration
|
At 240 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urine volume
Time Frame: 8 hours
|
Urine volume (ml) in urine collected 8 hours after start of SQIN-Furosemide infusion
|
8 hours
|
Sodium concentration in urine
Time Frame: 8 hours
|
Sodium concentration (mmol) in urine collected 8 hours after start of SQIN-Furosemide infusion
|
8 hours
|
Presence of local skin reactions
Time Frame: After 5 hour infusion
|
Presence of local skin reactions on examination
|
After 5 hour infusion
|
Patient acceptability
Time Frame: After 5 hour infusion
|
Patient acceptability using System Usability Scale - from 0 to 100 with a lower number correlating to poor usability and a higher number correlating to better usability by patients.
|
After 5 hour infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Mark Petrie, MBChB, University of Glasgow
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 6, 2021
Primary Completion (Actual)
August 13, 2021
Study Completion (Actual)
August 13, 2021
Study Registration Dates
First Submitted
April 12, 2021
First Submitted That Met QC Criteria
April 12, 2021
First Posted (Actual)
April 15, 2021
Study Record Updates
Last Update Posted (Actual)
November 26, 2021
Last Update Submitted That Met QC Criteria
November 16, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GN18CA193
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
to publish
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Duke University; St. Paul's Hospital... and other collaboratorsActive, not recruitingHeart Diseases | Heart Failure | Transplant; Failure, Heart | Heart Transplant Failure and Rejection | Heart Failure,Congestive | Transplant FailureCanada, United States
Clinical Trials on SQIN-01
-
Nordic Life Science Pipeline Inc.Completed
-
NHS Greater Glasgow and ClydeUniversity of GlasgowRecruiting
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Ixchelsis LimitedCompletedPremature EjaculationUnited States
-
Enterin Inc.TerminatedParkinson Disease | ConstipationUnited States
-
Zucara Therapeutics Inc.RecruitingType 1 Diabetes Mellitus With HypoglycemiaUnited States, Canada
-
Shanghai Hongyitang Biopharmaceutical Technology...Completed
-
Zhongmou TherapeuticsRecruitingX-linked RetinoschisisChina
-
BioPharmX, Inc.CompletedAcne VulgarisUnited States
-
Enterin Inc.CompletedParkinson Disease | ConstipationUnited States